In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Humacyte (HUMA - Research Report), with a price target of $10.00. The company's shares opened today at $4.27.According to TipRanks, Zimmerman is a 5-star analyst with an average return of 9.2% and a 45.82% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Humacyte, Vericel, and Mediwound.Humacyte has an analyst consensus of Moderate Buy, with a price target consensus of $7.17.See the top stocks recommended by analysts >>The company has a one-year high of $17.45 and a one-year low of $3.07. Currently, Humacyte has an average volume of 482.3K.
https://www.tipranks.com/news/blurbs/humacyte-huma-gets-a-buy-from-btig?utm_source=advfn.com&utm_medium=referral